Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

<p>Abstract</p> <p>Background</p> <p>Previous randomized studies have demonstrated that fesoterodine significantly improves the Overactive Bladder (OAB) symptoms and their assessment by patients compared with tolterodine extended-release (ER). This study aimed to assess...

Full description

Bibliographic Details
Main Authors: Castro-Diaz David, Miranda Pilar, Sanchez-Ballester Francisco, Lizarraga Isabel, Arumí Daniel, Rejas Javier
Format: Article
Language:English
Published: BMC 2012-07-01
Series:BMC Urology
Subjects:
Overactive bladder
Fesoterodine
Tolterodine ER
Dose escalation
Age
Patient-reported treatment benefit
Online Access:http://www.biomedcentral.com/1471-2490/12/19

Internet

http://www.biomedcentral.com/1471-2490/12/19

Similar Items